Cathie's Ark Logo
Intellia Therapeutics Inc Logo

Combined Holdings of Intellia Therapeutics (NTLA) - Updated Daily

Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing

Key Statistics

⚖️Weighting🧢Market Cap
🏋️‍♀️Weight Rank Across All Funds🌏Country
17🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$54.51 - ARKG$62.04 - ARKK
intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the

Other ETFs That Hold NTLA

ARKGARK Genomic Revolution ETF3.95%
ARKKARK Innovation ETF3.77%
GNOMGlobal X Genomics & Biotechnology ETF3.28%
XBISPDR® S&P Biotech ETF1.12%
IBBiShares Biotechnology ETF0.31%
LABUS&P Biotech Bull 3X Shares ETF0.24%

Research Notes and Commentary for NTLA

No Research Notes Found for NTLA